Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 95 results for template

  1. Charging timeline

    A timeline showing where in the NICE evaluation process companies will be charged.

  2. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  3. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  4. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  5. NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website

  6. Planning your technology appraisal submission to NICE

    Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.

  7. How we support healthtech commissioning

    practical support tools including real-life case studies and resource impact templates. Further resources and funding We understand that...

  8. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

  9. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  10. What is technology appraisal guidance?

    NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.

  11. Learning disability: care and support of people growing older (QS187)

    This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.

  12. Resource planner

    Our resource planner tool to help you plan for and implement NICE guidance.

  13. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  14. ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (HTG602)

    Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.

  15. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs